StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Investment analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $1.04 on Wednesday. The company has a 50 day simple moving average of $1.07 and a two-hundred day simple moving average of $1.05. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a market capitalization of $56.87 million, a price-to-earnings ratio of -2.89 and a beta of 0.78. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new stake in Cytosorbents in the 4th quarter worth about $30,000. Renaissance Technologies LLC grew its stake in shares of Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after acquiring an additional 8,400 shares during the period. Northern Trust Corp raised its holdings in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 16,701 shares during the last quarter. Raymond James Financial Inc. bought a new position in Cytosorbents during the fourth quarter valued at approximately $99,000. Finally, Geode Capital Management LLC boosted its holdings in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.